Hershey, PA & Rockville, MD (PRWEB) May 19, 2014
Immunomic Therapeutics, Inc. (ITI), a vaccine pioneer in the biotechnology industry, is proud to announce that the company’s CEO, Dr. William G. Hearl, will be a featured panelist at the prestigious Future in Review (FiRe) Conference hosted by Strategic News Service (SNS). SNS is the world’s most reliable source of advanced information at the intersection of technology and economics.
Tabbed by The Economist as “the best technology conference in the world,” the annual FiRe event features global thought leaders in technology and the world economy. Dr. Hearl joins a panel of preeminent experts in a discussion of ideas that are expected to shape the future of technology.
Dr. Hearl will be featured in a panel discussion on Wednesday, May 21 at 10:45 a.m. ET, hosted by Ed Butler of the BBC. Panelists are named from organizations chosen by SNS as “FiReStarter companies” for their innovations in technology and their potential to bring positive change to the world. FiReStarter companies are believed to be on the cutting edge of scientific and transformative breakthroughs.
“It is an honor to be invited as a panelist at one of the world’s most regarded conferences, and to present alongside these groundbreaking companies,” Dr. Hearl said. “This is an exciting time for ITI. Our technology has us on the cusp of dramatic breakthroughs in vaccines that will change people’s lives forever. We’re ready to share our story with the world, and there is no better place to tell it than at the FiRe Conference.”
Dr. Hearl will discuss ITI’s LAMP-vax™ Technology, described as the missing link in enhancing the effectiveness of DNA vaccines. The technology makes DNA vaccines work and could reign in an era of simple, inexpensive and effective vaccinations for many diseases. LAMP immunotherapy formulations have been found to be safe and immunogenic for patients with prostate cancer, acute myeloid leukemia and melanoma.
“While DNA and other nucleic acid vaccines have been in development since the 1990s, our technologies can finally make them a reality,” said Dr. Hearl. “LAMP-vax is a class of vaccines that is pioneering the vaccine industry and delivers the potential to transform human life.”
ITI has drawn the attention of the pharmaceutical and allergy community with its JRC-LAMP-Vax product, a vaccine that targets the Japanese red cedar allergy in Japan. The Phase I clinical trial results hint at a potentially high effectiveness rate based on an 80%-90% conversion of allergic skin tests from positive to negative. On its heels is ARA-LAMP-Vax, a vaccine that could safely resolve peanut allergies in children around the world. Meanwhile, together with a leading pharmaceutical company, ITI is also applying its technology to the animal health arena. That work has already demonstrated strong immune responses in studies in dogs.
ITI’s R&D team is known for its expertise in molecular biology and immunology. It advances LAMP in collaboration with other technologies that deliver properly designed vaccines to the right immune cell populations in the body. ITI is illuminating how LAMP-vax vaccines improve the immune response and complement and enable other vaccine programs. It focuses on next-generation LAMP-vax vaccines with innovations and quality measures that outpace other industry attempts. The company collaborates with researchers at leading institutions such as Duke University, who have applied LAMP technology in immunotherapies to treat cancers such as glioblastoma.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company headquartered in Lancaster, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit http://www.immunomix.com or contact Kristi Hughes at MKJ Creative khughes(at)mkjcreative.com